Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan I Silverberg

Showing results (481-490 of 545) with videos related to

Pageof 55
Sort By:
Dermatitis : Contact, Atopic, Occupational, Drug|April 19, 2021
Patch Testing to Carvone: North American Contact Dermatitis Group Experience, 2009 to 2018Erin M Warshaw, Rob L Shaver, Joel G DeKoven, et al.
The British Journal of Dermatology|January 23, 2025
Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)Jonathan I Silverberg, Lawrence F Eichenfield, Andrew Blauvelt, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 9, 2020
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical TrialsJonathan I Silverberg, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|May 13, 2022
Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018Erin M Warshaw, Michelle Xiong, Amber R Atwater, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|December 4, 2020
Fragrance- and Botanical-Related Allergy and Associated Concomitant Reactions: A Retrospective Analysis of the North American Contact Dermatitis Group Data 2007-2016Amber Reck Atwater, Jordan Maxwell Ward, Beiyu Liu, et al.
Journal of the American Academy of Dermatology|December 1, 2020
Hand dermatitis in adults referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2000 to 2016Jonathan I Silverberg, Erin M Warshaw, Amber R Atwater, et al.
Dermatology and Therapy|May 2, 2024
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)Eric L Simpson, Vimal H Prajapati, Yael A Leshem, et al.
Acta Dermato-Venereologica|June 11, 2026
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic DermatitisAndreas Wollenberg, Jonathan I Silverberg, Franz J Legat, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 16, 2020
Patch Testing to Diphenylguanidine by the North American Contact Dermatitis Group (2013-2016)Erin M Warshaw, Rachit Gupta, Joel G Dekoven, et al.
Journal of the American Academy of Dermatology|December 7, 2021
Medical adhesive allergens: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2018Amber Reck Atwater, Raina Bembry, Beiyu Liu, et al.
Pageof 55

Showing results (481-490 of 545) with videos related to

Sort By:
Pageof 55
Dermatitis : Contact, Atopic, Occupational, Drug|April 19, 2021
Patch Testing to Carvone: North American Contact Dermatitis Group Experience, 2009 to 2018Erin M Warshaw, Rob L Shaver, Joel G DeKoven, et al.
The British Journal of Dermatology|January 23, 2025
Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)Jonathan I Silverberg, Lawrence F Eichenfield, Andrew Blauvelt, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 9, 2020
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical TrialsJonathan I Silverberg, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|May 13, 2022
Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018Erin M Warshaw, Michelle Xiong, Amber R Atwater, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|December 4, 2020
Fragrance- and Botanical-Related Allergy and Associated Concomitant Reactions: A Retrospective Analysis of the North American Contact Dermatitis Group Data 2007-2016Amber Reck Atwater, Jordan Maxwell Ward, Beiyu Liu, et al.
Journal of the American Academy of Dermatology|December 1, 2020
Hand dermatitis in adults referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2000 to 2016Jonathan I Silverberg, Erin M Warshaw, Amber R Atwater, et al.
Dermatology and Therapy|May 2, 2024
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)Eric L Simpson, Vimal H Prajapati, Yael A Leshem, et al.
Acta Dermato-Venereologica|June 11, 2026
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic DermatitisAndreas Wollenberg, Jonathan I Silverberg, Franz J Legat, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 16, 2020
Patch Testing to Diphenylguanidine by the North American Contact Dermatitis Group (2013-2016)Erin M Warshaw, Rachit Gupta, Joel G Dekoven, et al.
Journal of the American Academy of Dermatology|December 7, 2021
Medical adhesive allergens: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2018Amber Reck Atwater, Raina Bembry, Beiyu Liu, et al.
Pageof 55